Gout: diagnosis and initial tests
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Suspected gout: confirm the diagnosis
- Fever, impaired general condition or doubt about septic arthritis: opinion or emergency department without waiting for the tests.
Laboratory tests
- Serum urate (if normal during the flare, recheck it at least 2 weeks later)
- Joint fluid examination: crystals, cytology, bacteriology (if aspiration feasible)if needednon-French guidelineAs soon as a tap is possible: testing for urate crystals is recommended in anyone with suspected gout and in any patient with undiagnosed inflammatory arthritis [1]; failing that, at least when the diagnosis remains uncertain [2].
Do not order
Confirmed gout: initial tests (comorbidities, before urate-lowering therapy)
Fasting laboratory tests, away from the attack
- Serum urate (baseline value)
- Serum creatinine with eGFR
- Fasting plasma glucose
- Lipid profile
- ASTif neededBefore starting febuxostat: the SmPC recommends liver function tests before initiation then periodically [5].
- ALTif neededBefore starting febuxostat: the SmPC recommends liver function tests before initiation then periodically [5].
- HLA-B*5801 allele testing (before allopurinol, if South-East Asian or African-American origin)if needednon-French guidelinePatients of South-East Asian (Han Chinese, Korean, Thai) or African American origin, in whom the allele, associated with severe hypersensitivity reactions to allopurinol, is more frequent [6].
Also consider
- Urate-lowering therapy started? Once maintenance treatment has started, monitoring is in the page "Treatment: urate-lowering therapy (allopurinol, febuxostat)".
Do not order
- HLA-B*5801 in all patients before allopurinol: not advised outside South-East Asian or African American origin [6].
Sources (10)
- Richette P, Doherty M, Pascual E, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020;79(1):31-8.
- National Institute for Health and Care Excellence. Gout: diagnosis and management. NICE guideline NG219, juin 2022 (recommandations 1.1, 1.3.6, 1.4, 1.5).
- Qaseem A, McLean RM, Starkey M, Forciea MA; Clinical Guidelines Committee of the American College of Physicians. Diagnosis of Acute Gout: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017;166(1):52-57.
- Clebak KT, Morrison A, Croad JR. Gout: Rapid Evidence Review. Am Fam Physician. 2020;102(9):533-538.
- Agence européenne des médicaments. Adenuric (fébuxostat) : résumé des caractéristiques du produit (information produit EPAR), rubrique 4.4, consulté le 11 octobre 2026.
- FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72(6):744-60.
- Pascart T, Latourte A, Flipo RM, et al. 2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy. Joint Bone Spine. 2020;87(5):395-404.
- Leung N, Yip K, Pillinger MH, Toprover M. Lowering and raising serum urate levels: off-label effects of commonly used medications. Mayo Clin Proc. 2022;97(7):1345-62.
- Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42.
- Zorginstituut Nederland. Farmacotherapeutisch Kompas : allopurinol (texte du médicament, rubriques « Advies » et « Dosering », posologie de la NHG-Standaard Artritis 2017), consulté le 29/10/2026.